Mammalian target of rapamycin complex 1 (mTORC1) inhibitors are extensively used as immunosuppressants to prevent transplant rejection and in treatment of certain cancers. In patients, chronic treatment with rapamycin or its analogues (rapalogues) has been reported to lead to sensory hypersensitivity and pain conditions via an unknown mechanism. Here, we show that pharmacological or genetic inhibition of mTORC1 activates the extracellular signal-regulated kinase (ERK) pathway in sensory neurons via suppression of S6K1 to insulin receptor substrate 1 negative feedback loop. As a result, increased ERK activity induces sensory neuron sensitization, mechanical hypersensitivity, and spontaneous pain. The clinically available adenosine monophosphate-activated protein kinase activator, metformin, which is an antidiabetic drug, prevents rapamycin-induced ERK activation and the development of mechanical hypersensitivity and spontaneous pain. Taken together, our findings demonstrate that activation of the ERK pathway in sensory neurons as a consequence of mTORC1 inhibition leads to the development of pain. Importantly, this effect is abolished by co-treatment with metformin, thus providing a potential treatment option for rapalogue-evoked pain. Our findings highlight the physiological relevance of feedback signaling through mTORC1 inhibition and have important implications for development of pain therapeutics that target the mTOR pathway. Ó
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Introduction
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that regulates growth and proliferation, translation, autophagy, and cytoskeleton organization. mTOR has recently emerged as a potential target for the treatment of pain because mTOR activation has been linked to pathology underlying neuropathic pain at both peripheral and spinal levels [2, 19, 28, 34] . mTOR complex 1 (mTORC1) exerts its effect via phosphorylation of its 2 key substrates, p70 S6 kinase (S6K; of which there are 2 members, S6K1 and S6K2) and eIF4E-binding proteins. When phosphorylated by mTORC1, S6K1 stimulates mRNA translation by phosphorylating proteins that control translation initiation and elongation [53] . As part of a negative feedback loop, S6K1 also phosphorylates and inhibits insulin receptor substrate 1 (IRS-1), leading to inhibition of AKT (protein kinase B)-mTOR and extracellular signal-regulated kinase (ERK) signaling. With long-term mTORC1 inhibition, decreased S6K1 activity leads to disinhibition of IRS-1, resulting in enhanced AKT [7, 22, 33] and ERK [16] activity in cells. Because increased ERK activity is a well-known sensitizer of peripheral nociceptors and is also involved in sensitization of spinal cord neurons in the pain pathway [20, 27] , we reasoned that this feedback activation of ERK might be physiologically relevant for therapeutics targeting mTORC1 in the pain pathway. Interestingly, chronic treatment of patients with mTORC1 inhibitors is associated with increases in the incidence of pain [6, 26] , including the possible development of complex regional pain syndrome (CRPS) [24, 31, 47] ; however, mechanistic data are lacking concerning whether and how rapalogues are linked to the development of pain in patients treated with these drugs. 
